Continued Access to RXDX-105
This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.
Checked against the public recordLast updated May 15, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Interventions being studied
- Drug: RXDX-105
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * This individual patient protocol includes treatment for 3 patients previously enrolled on IRB #15-270 (phase1/1b clinical trial RXDX-105-01): Exclusion Criteria: * Any patients other than those described above are excluded.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Memorial Sloan Kettering Cancer Center 1275 York AvenueNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 15, 2025. Always confirm current availability with the study team.